Retrospective, Non-interventional Study of Depo-Eligard®.

Study to Find Maintenance Dose for Periodic Administration of ASP3550

NCT01261572 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

NCT01442246 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy

NCT03080116 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Evaluate Recovery of Testosterone for Patients Using Eligard

NCT01136226 ·Status: COMPLETED ·Phase: PHASE4

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease

NCT01933022 ·Status: TERMINATED ·Phase: PHASE4

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

NCT00541281 ·Status: COMPLETED ·Phase: PHASE2

A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy

NCT01302041 ·Status: COMPLETED ·Phase: PHASE2

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

NCT01793077 ·Status: COMPLETED

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

NCT00257478 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

NCT00411528 ·Status: COMPLETED ·Phase: PHASE2

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

NCT06130995 ·Status: RECRUITING ·Phase: PHASE1

A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer

NCT01964170 ·Status: COMPLETED ·Phase: PHASE3

Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

NCT00654186 ·Status: COMPLETED ·Phase: PHASE2

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

NCT00510718 ·Status: COMPLETED ·Phase: PHASE1

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients

NCT01995513 ·Status: COMPLETED ·Phase: PHASE4

EPO906 Therapy in Patients With Prostate Cancer

NCT00035113 ·Status: COMPLETED ·Phase: PHASE2

Study of CEP-701 in Treatment of Prostate Cancer

NCT00081601 ·Status: COMPLETED ·Phase: PHASE2

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

NCT05352178 ·Status: RECRUITING ·Phase: PHASE3

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

NCT01212991 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

NCT00172055 ·Status: COMPLETED ·Phase: PHASE3

Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer

NCT01558427 ·Status: COMPLETED ·Phase: PHASE2

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

NCT05534646 ·Status: RECRUITING ·Phase: PHASE2

Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

NCT00407251 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

NCT01511874 ·Status: COMPLETED ·Phase: PHASE4